Abstract
The role of plasma and serum proteomics in characterizing human disease, identifying biomarkers, and advancing diagnostic technologies is rapidly increasing. However, there is an ongoing need to improve proteomic workflows in terms of accuracy, reproducibility, platform transferability, and cost-effectiveness. Here, we present the Charité Open Peptide Standard for Plasma Proteomics (OSPP), a panel of 211 extensively pre-selected, stable-isotope-labeled peptides combined in an open, versatile, and cost-effective internal standard for targeted and untargeted proteomic studies. The selected peptides are well suited for chemical synthesis, and distribute well over the captured analytical dynamic range and chromatographic gradients, and show consistent quantification properties across platforms, in serum, as well as in EDTA-, citrate, and heparin plasma. Quantifying proteins that function in a wide range of biological processes, including several that are routinely used in clinical tests or are targets of FDA-approved drugs, the OSPP quantifies proteins that are important for human disease. On an acute COVID-19 in-patient cohort, we demonstrate the application of the OSPP to i) achieve patient classification and biomarker identification ii) generate comparable quantitative proteomics data with both targeted and untargeted approaches, and iii) estimate peptide quantities for successful cross-platform alignment of proteomic data. The OSPP adds low costs per proteome sample, thus making the use of an internal standard accessible. In addition to the standards, corresponding spectral libraries and optimized acquisition methods for several platforms are made openly available.
Competing Interest Statement
Markus Ralser is founder and shareholder, while Michael Muelleder and Ziyue Wang are advisors, and Luise Luckau is an Employee of Elitpca. Ltd.
Funding Statement
This work was supported by the Ministry of Education and Research (BMBF), as part of the National Research Node Mass Spectrometry in Systems Medicine (MSCoreSys), under grant agreements 16LW0239K (to M.M.), 01EP2201 (to M.R.), the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) 492697668 and the European Research Council (ERC SyG-2020 951475). This work was further supported by a BIH Booster Grant (2022-B3020086-11/12 to Z.W., P.T-L., F.K., J.H. M.M, M.R.) and DKTK under grant agreement BE01 1020000483. Z.W. is a member of the International Max Planck Research School (IMPRS) for Infectious Diseases and Immunology, and the Deutsche Forschungsgemeinschaft (DFG) funded Sonderforschungsbereich (SFB) TRR 186.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The COVID-19 cohort is a subcohort of the Pa-COVID-19 study, which is carried out according to the Declaration of Helsinki and the principles of Good Clinical Practice (ICH 1996) where applicable and was approved by the ethics committee of Charite- Universitaetsmedizin Berlin (EA2/066/20).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
We have made the following revisions to improve the clarity, technical detail, and overall presentation of our manuscript: 1)Figures 3 and 4 Updated: Figures 3 and 4 have been updated to include additional technical information, enhancing their explanatory value. 2)Figure 6 Removed and Merged with figure 5: Figure 6 has been removed. Key information from this figure has been integrated into Figure 5, providing a more coherent and easily understandable presentation of the results and the OSPP summary. 3)Restructured Results Section: The results section for figure 3,4,5 has been reorganized to incorporate more technical details, improving clarity and logical flow. 4)Supplementary Materials Updated: Relevant supplementary materials have been revised to align with updates made to the main text and figures. 5)Discussion Section Updated: The discussion has been refined to reflect the restructured results section and provide a more cohesive analysis based on the updated findings. These changes were made to ensure greater clarity, alignment with the updated content, and improved readability for the intended audience. 6)Co-Corresponding Authors Designation: Based on contributions to the revised manuscript, we have decided to include Michael Muelleder and Markus Ralser as co-corresponding authors for this manuscript. These changes were made to ensure greater clarity, alignment with the updated content, and improved readability for the intended audience.
Data Availability
All data produced in the present work are contained in the manuscript, or available online at Mendeley Data.
